Decline in product sales revenue following completion of a major server replacement order from a major customer
First written in FY2018-Q3. 2 of 15 entries say "Restated". Latest entry: FY2023-Q3.
No other company in this theme has enough history to compare yet.
- FY2023-Q3RestatedAnnual report
「As all shares of 株式会社マーベラント, the operating company of the medical and anti-aging business, were transferred in the previous consolidated fiscal year, this segment recorded no revenue for the first nine months of the current consolidated fiscal year.」
The company continues to report no revenue in the Other segment following the transfer of all shares of マーベラント. - FY2023-Q1Loss of revenue following the business transferAnnual report
「As all shares of 株式会社マーベラント, the operating company of the medical and anti-aging business, were transferred in the previous consolidated fiscal year, this segment recorded no revenue for the first quarter of the current consolidated fiscal year.」
The company states that the Other segment generated no revenue in the quarter following the transfer of all shares of マーベラント. - FY2022-Q2Business transfer following higher revenue and profit from the medical mallAnnual report
「In the medical and anti-aging business operated by a subsidiary, which provides management services for a medical mall, tenant occupancy remained stable and revenue was ¥42.682 million, up 5.6% year on year. Segment profit was ¥4.308 million, up 18.9% year on year. In addition, all shares of 株式会社マーベラント, the consolidated subsidiary responsible for this business, were transferred to ホーイズム株式会社 on 28 September 2021.」
The medical mall business recorded higher revenue and profit as tenant occupancy remained stable, while all shares of マーベラント, the company responsible for the business, were transferred on 28 September 2021. - FY2022-Q1Stable medical mall operations and a return to profitabilityAnnual report
「In the medical and anti-aging business operated by a subsidiary, which provides management services for a medical mall, tenant occupancy remained stable and revenue was ¥20.441 million, up 2.7% year on year. Segment profit was ¥1.643 million, compared with a loss of ¥126 thousand in the same period of the previous year.」
Tenant occupancy at the medical mall remained stable, increasing revenue and turning the segment from a loss in the same period of the previous year to a profit. - FY2021-Q3Continued revenue decline following the withdrawal from cosmetics salesAnnual report
「In the medical and anti-aging business operated by a subsidiary, which manages a medical mall, tenant occupancy increased, but revenue was ¥60.737 million, down 13.3% year on year, following the withdrawal from cosmetics sales. Segment profit was ¥5.775 million, down 7.8% year on year, due to the impact of upfront investment in facilities.」
Although tenant occupancy at the medical mall increased, revenue and segment profit were below the same period of the previous year due to the withdrawal from cosmetics sales and upfront investment in facilities. - FY2021-Q2Continued revenue decline following the withdrawal from cosmetics salesAnnual report
「In the medical and anti-aging business operated by a subsidiary, which provides management services for a medical mall, tenant occupancy finally increased, but revenue was ¥40.383 million, down 15.4% year on year, following the withdrawal from cosmetics sales. Segment profit was ¥3.621 million, down 43.5% year on year, due to the impact of upfront investment in facilities.」
The withdrawal from cosmetics sales is explicitly identified as a factor behind the decline in revenue in the Other segment. Tenant occupancy at the medical mall increased, but revenue and profit were below the same period of the previous year. - FY2020Continued revenue and profit growth from security package software salesAnnual report
「In product sales, revenue was ¥57.648 million, up 16.3% from the previous period, and segment profit was ¥6.506 million, compared with segment profit of ¥393 thousand in the previous period, following a focus on sales of security package software.」
The focus on security package software sales increased product sales revenue and segment profit from ¥393 thousand to ¥6.506 million. - FY2020-Q3Continued revenue and profit growth from security package software salesAnnual report
「In product sales, revenue was ¥52.933 million, up 40.1% year on year, and segment profit was ¥5.356 million, compared with segment profit of ¥226 thousand in the same period of the previous year, following a focus on sales of security package software.」
The focus on security package software sales increased revenue by 40.1% year on year and segment profit from ¥226 thousand to ¥5.356 million. - FY2020-Q2Higher revenue and profit from security package software salesAnnual report
「In product sales, revenue was ¥52.447 million, up 105.5% year on year, and segment profit was ¥4.030 million, compared with segment profit of ¥151 thousand in the same period of the previous year, following a focus on sales of security package software.」
The focus shifted from the previous cosmetics sales business to security package software sales, increasing product sales revenue by 105.5% year on year and segment profit from ¥151 thousand to ¥4.030 million. - FY2020-Q1Declining revenue and a return to a loss following the end of the cosmetics agency agreementAnnual report
「In product sales, revenue was ¥9.713 million, down 26.2% year on year, and the segment recorded a loss of ¥122 thousand, compared with a segment profit of ¥1.284 million in the same period of the previous year, mainly because the cosmetics agency agreement operated by 株式会社ヴァージンメディカル ended in May 2019.」
The cosmetics agency agreement ended in May 2019, resulting in lower product sales revenue and a shift from the segment profit recorded in the same period of the previous year to a loss. - FY2019Higher revenue and a return to profitability from cosmetics salesAnnual report
「In product sales, revenue was ¥49.582 million, up 51.6% from the previous period, due to cosmetics sales by 株式会社ヴァージンメディカル, a consolidated subsidiary, and the segment recorded a profit of ¥393 thousand, compared with a segment loss of ¥1.772 million in the previous period.」
Cosmetics sales by 株式会社ヴァージンメディカル lifted product sales revenue by 51.6% from the previous period and turned the segment from a loss into a profit. - FY2019-Q2Continued revenue growth from cosmetics salesAnnual report
「In product sales, revenue was ¥25.522 million, up 349.0% year on year, due to the recognition of revenue from cosmetics sales by 株式会社ヴァージンメディカル, a consolidated subsidiary, while segment profit was ¥151 thousand, up 7.3% year on year.」
Higher revenue and profit from cosmetics sales have continued, replacing the previous explanation of a revenue decline caused by the end of the major server replacement order. - FY2019-Q1ReframedAnnual report
「In product sales, revenue was ¥13.157 million, compared with ¥1.109 million in the same period of the previous year, and the segment recorded a profit of ¥1.284 million, compared with a segment profit of ¥89 thousand in the same period of the previous year, mainly because 株式会社ヴァージンメディカル began cosmetics sales in October 2017.」
The explanation for product sales has shifted from the previous explanation of a revenue decline due to the end of the major server replacement order from a major customer to an explanation of higher revenue and profit due to the start of cosmetics sales by 株式会社ヴァージンメディカル. - FY2018RestatedAnnual report
「In product sales, 株式会社ヴァージンメディカル, a consolidated subsidiary, resumed its cosmetics sales business, but revenue was ¥32.711 million, down 74.0% year on year, and the segment recorded a loss of ¥1.772 million, compared with a segment loss of ¥19.333 million in the previous period, mainly because the major server replacement order recorded in the previous consolidated fiscal year had ended.」
The company continues to cite the completion of the major server replacement order from a major customer in the previous period as a factor behind the full-year decline in product sales revenue. - FY2018-Q3First statedAnnual report
「In product sales, revenue was ¥18.415 million, down 83.4% year on year, and the segment recorded a loss of ¥1.422 million, compared with a segment loss of ¥16.321 million in the same period of the previous year, mainly because the major server replacement order from a major customer in the previous consolidated fiscal year was completed in the prior period.」
The company explicitly identifies the completion of the major server replacement order in the previous period as a factor behind the decline in product sales revenue for the first time.